Australia markets open in 1 hour 13 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
783.13+31.93 (+4.25%)
At close: 04:00PM EST
784.15 +1.02 (+0.13%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close751.20
Bid782.90 x 1000
Ask785.00 x 900
Day's range758.63 - 789.95
52-week range538.01 - 789.95
Avg. volume651,804
Market cap85.284B
Beta (5Y monthly)0.24
PE ratio (TTM)16.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

    Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%Fourth quarter 2022 EYLEA® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021; full year 2022 EYLEA U.S. net sales increased 8% to $6.26 billion versus 2021Fourth quarter 2022 Dupixen

  • GlobeNewswire

    Regeneron Announces Investor Conference Presentations

    TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Securities Global Biopharma Conference at 9:20 a.m. ET on Tuesday, February 14, 2023Cowen 43rd Annual Health Care Conference at 12:50 p.m. ET on Monday, March 6, 2023Oppenheimer 33rd Annual Healthcare Conference at 9:20 a.m. ET on Monday, March 13, 2023Barclays Global Healthcare Conference at 9:00 a.m. ET on Wednesday, March 15, 2023 The sessions

  • GlobeNewswire

    Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

    Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagitis in the European Union (EU) Dupixent now approved to treat five diseases with underlying type 2 inflammation in the EU TARRYTOWN,